Invion Ltd. (AU:IVX) has released an update.
Invion Limited has announced the issuance of 180 million fully paid ordinary shares, issued without disclosure to Lind Global Fund II, LP, in accordance with Section 708A of the Corporations Act. The company confirms compliance with all relevant provisions of the Corporations Act and reports no excluded information as of the announcement date. Invion is known for leading the global R&D of Photosoft™ technology for cancer treatment and holds the license rights in Australia and New Zealand.
For further insights into AU:IVX stock, check out TipRanks’ Stock Analysis page.
